Stem definition | Drug id | CAS RN |
---|---|---|
2282 | 500-92-5 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 9.09 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
July 14, 2000 | FDA | GLAXOSMITHKLINE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malaria | 157.89 | 32.45 | 23 | 1693 | 219 | 46684127 |
Hypomania | 111.62 | 32.45 | 27 | 1689 | 4361 | 46679985 |
Jaundice cholestatic | 98.04 | 32.45 | 25 | 1691 | 5004 | 46679342 |
Schizophrenia | 93.71 | 32.45 | 27 | 1689 | 8541 | 46675805 |
Psychotic disorder | 93.33 | 32.45 | 34 | 1682 | 22587 | 46661759 |
Blood bilirubin increased | 63.51 | 32.45 | 29 | 1687 | 34155 | 46650191 |
Hepatotoxicity | 62.00 | 32.45 | 26 | 1690 | 24983 | 46659363 |
Congenital absence of cranial vault | 53.23 | 32.45 | 7 | 1709 | 28 | 46684318 |
Cholelithiasis | 51.16 | 32.45 | 26 | 1690 | 38655 | 46645691 |
Neural tube defect | 47.97 | 32.45 | 8 | 1708 | 192 | 46684154 |
Hepatic enzyme increased | 42.24 | 32.45 | 30 | 1686 | 81757 | 46602589 |
Exposure during pregnancy | 38.93 | 32.45 | 32 | 1684 | 108180 | 46576166 |
Dermatitis acneiform | 36.46 | 32.45 | 11 | 1705 | 4059 | 46680287 |
Plasmodium falciparum infection | 34.26 | 32.45 | 5 | 1711 | 48 | 46684298 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malaria | 150.21 | 30.85 | 22 | 1079 | 219 | 29951158 |
Plasmodium falciparum infection | 52.85 | 30.85 | 7 | 1094 | 30 | 29951347 |
Hallucination | 37.56 | 30.85 | 23 | 1078 | 49036 | 29902341 |
Abnormal dreams | 32.70 | 30.85 | 12 | 1089 | 8103 | 29943274 |
Source | Code | Description |
---|---|---|
ATC | P01BB01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Biguanides |
ATC | P01BB51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Biguanides |
FDA MoA | N0000000191 | Dihydrofolate Reductase Inhibitors |
FDA EPC | N0000175482 | Antimalarial |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000962 | Antimalarials |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D000977 | Antiparasitic Agents |
MeSH PA | D000981 | Antiprotozoal Agents |
MeSH PA | D009676 | Noxae |
CHEBI has role | CHEBI:35820 | antiprotozoal agent |
CHEBI has role | CHEBI:38068 | antimalarials |
CHEBI has role | CHEBI:50683 | 7,8-dihydrofolate reductase inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Falciparum malaria | indication | 62676009 | DOID:14067 |
Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention | indication | ||
Plasmodium Falciparum Malaria Prevention | indication | ||
Vivax malaria | off-label use | 27052006 | DOID:12978 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Chronic diarrhea | contraindication | 236071009 | |
Vomiting | contraindication | 422400008 | |
Malabsorption States | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.73 | Basic |
pKa2 | 2.36 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Bifunctional dihydrofolate reductase-thymidylate synthase | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
Bifunctional dihydrofolate reductase-thymidylate synthase | Enzyme | WOMBAT-PK | |||||||
Bifunctional dihydrofolate reductase-thymidylate synthase | Enzyme | WOMBAT-PK |
ID | Source |
---|---|
4021225 | VUID |
N0000148669 | NUI |
D02487 | KEGG_DRUG |
637-32-1 | SECONDARY_CAS_RN |
4021225 | VANDF |
C0008241 | UMLSCUI |
CHEBI:8455 | CHEBI |
CHEMBL1377 | ChEMBL_ID |
CHEMBL1201059 | ChEMBL_ID |
DB01131 | DRUGBANK_ID |
D002727 | MESH_DESCRIPTOR_UI |
6178111 | PUBCHEM_CID |
9676 | IUPHAR_LIGAND_ID |
418 | INN_ID |
S61K3P7B2V | UNII |
142428 | RXNORM |
15669 | MMSL |
d04593 | MMSL |
002942 | NDDF |
002943 | NDDF |
16970001 | SNOMEDCT_US |
387094004 | SNOMEDCT_US |
395845004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0675 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 24 sections |
MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0676 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 24 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-4160 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 27 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-4162 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-909 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 33261-900 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42254-150 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43063-393 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43063-522 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 26 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1302 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-2980 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 27 sections |
Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-2980 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 27 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6393 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 55289-747 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 24 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60760-498 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63187-879 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-5531 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 26 sections |
Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 66993-060 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 26 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68001-245 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68258-1104 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Atovaquone and Proguanil Hydrochloride Pediatric | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68462-402 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 26 sections |
Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68462-404 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |